Inovio wins prestigious Edward Jenner Poster Award for cervical cancer vaccine research
Inovio Pharmaceuticals (AMEX:INO) won the Edward Jenner Poster Award First Prize for its research to develop a therapeutic, synthetic vaccine for cancer.
Proactive Investors
Advanced Cell receives green light from independent monitoring board to move forward with US trials
Advanced Cell Technology (OTCBB:ACTC) has received approval to move forward with enrolling and treating the next set of patients.
QLT receives two fast track designations for degenerative eye disease drug
QLT (TSE:QLT) (NASDAQ:QLTI) announced Wednesday it received two fast track designations from the U.S. FDA
NanoViricides Reports Positive Anti-viral Effect of HIV Drug
NanoViricides’ anti-HIV drug candidate, HIVCide, achieved a positive, long-term effect with fewer and weaker doses than the traditional anti-retroviral combination therapy.
Bacterin Receives $15 Million Credit Facility
Bacterin International Holdings (AMEX:BONE) announced Tuesday it secured a 42 month-long, $15 million credit facility with MidCap Financial LLC and Silicon Valley Bank.
IntelliCell BioSciences To Open Adipose Tissue Processing Center in Houston
IntelliCell BioSciences, Inc. (OTCQB: SVFC), maker of stromal vascular fraction that contains adipose derived adult stem cells opens new processing center in Houston, Texas.
Bio-Rad receives pre-market approval for HIV test from FDA
Bio-Rad Laboratories (NYSE:BIO) announced Monday it received FDA premarket approval for its fourth generation human immunodeficiency virus (HIV) diagnostic test.
Drug maker GlaxoSmithKline receives upbeat results in Promacta phase three study
Biotech company Ligand Pharmaceuticals Inc. reported Tuesday that its partner GlaxoSmithKline received encouraging results in Hepatitis C study.
E-Therapeutics expects to generate a “wealth of data” from clinical trials
E-Therapeutics (LON:ETX) expects to generate a “wealth of data” from a clinical programme focusing on four drug candidates.
Inovio yields long-term immune responses from cervical cancer vaccine
Inovio Pharmaceuticals reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.